Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer and Eye Metastasis: Disease Relapse or a New Entity?

por ZAROGOULIDIS, Paul, LAMPAKI, Sofia, CHINELIS, Panos, LAZARIDIS, George, BAKA, Sofia, RAPTI, Aggeliki
Publicado 2016

“Liquid elbows” due to afatinib administration

por Zarogoulidis, Paul, Chinelis, Panos, Athanasiadou, Anastasia, Porpodis, Konstantinos, Kallianos, Anastasios, Rapti, Aggeliki, Trakada, Georgia, Velentza, Lemonia, Huang, Haidong, Tsiouda, Theodora, Hohenforst-Schmidt, Wolfgang
Publicado 2017

EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50%

por Zarogoulidis, Paul, Chinelis, Panos, Efthymiou, Christofors, Athanasiadou, Anastasia, Mpikos, Vasilis, Papatsibas, George, Papadopoulos, Vasilis, Maragouli, Elena, Huang, Haidong, Trakada, Georgia, Kallianos, Anastasios, Veletza, Lemonia, Hohenforst-Schmidt, Wolfgang
Publicado 2017

Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases

por Zarogoulidis, Paul, Chinelis, Panos, Athanasiadou, Anastasia, Tsiouda, Theodora, Trakada, Georgia, Kallianos, Anastasios, Veletza, Lemonia, Hatzibougias, Dimitris, Mihalopoulou, Electra, Goupou, Eirini, Kosmidis, Christoforos, Sardeli, Chrysanthi, Huang, Haidong, Hohenforst-Schmidt, Wolfgang
Publicado 2017